Pan-Sarvecovirus Neutralizing Antibodies in BNT162b2-immunized SARS-CoV-1 Survivors

August 18, 2021.

DOI: 10.1056 / NEJMoa2108453

Commentary

Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants pose challenges to vaccine efficacy. Many people want a vaccine that can prevent infections caused by these mutant strains and by pre-germinated salvecoviruses.

This study provides data on potent cross-clade pan-sarvecovirus neutralizing antibodies against persons with a history of severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) infection who were immunized with the BNT162b2 messenger RNA (mRNA) vaccine.

Results confirm that the antibodies are high-level and broad-spectrum, neutralizing not only known variants of concern, but also salvecoviruses that have been identified in bats and lepidopterans and can cause human infections.

These findings indicate the feasibility of a pan-sarvecovirus vaccine strategy, they said.